chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pregnancy loss; iron/ferritin deficiency; arm/leg tingles; heart flutters; GI slowness/issues; extreme fatigue; brain fog; excessive hair loss; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An adult female patient (unknown if pregnant) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose Number: 1 , manufacturer unknown. Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion), for Covid-19 immunization. The following information was reported: ABORTION SPONTANEOUS (medically significant), outcome "unknown", described as "pregnancy loss"; IRON DEFICIENCY (non-serious), outcome "unknown", described as "iron/ferritin deficiency"; PARAESTHESIA (non-serious), outcome "unknown", described as "arm/leg tingles"; CARDIAC FLUTTER (non-serious), outcome "unknown", described as "heart flutters"; GASTRIC DISORDER (non-serious), outcome "unknown", described as "GI slowness/issues"; FATIGUE (non-serious), outcome "unknown", described as "extreme fatigue"; FEELING ABNORMAL (non-serious), outcome "unknown", described as "brain fog"; ALOPECIA (non-serious), outcome "unknown", described as "excessive hair loss". It was unknown if therapeutic measures were taken as a result of abortion spontaneous, iron deficiency, paraesthesia, cardiac flutter, gastric disorder, fatigue, feeling abnormal, alopecia.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
It was 3 does 2 on left leg 4 different vaccines in 2 does and one vaccines one dose on right leg.
My skin color got lighter in a perfect circle about 2 inches in diameter at vaccine site. Hasn't gone away. No redness or itching not a rash. Almost as if it was bleached; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 16:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 12:00 the patient experienced "My skin color got lighter in a perfect circle about 2 inches in diameter at vaccine site. Hasn't gone away. No redness or itching not a rash. Almost as if it was bleached". The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event "My skin color got lighter in a perfect circle about 2 inches in diameter at vaccine site. Hasn't gone away. No redness or itching not a rash. Almost as if it was bleached "was not recovered at the time of this report.   No follow-up attempts are needed; information about lot number cannot be obtained.
pt recvd vax & devel t102-104 & sz; also roseola;
8 days post vaccine I developed a small rash around injection site. 36 hour post development of rash, the rash has tripled in size.
I developed acute onset major depressive disorder. After several ER visits entered into intensive outpatient program. Had suicide ideation for 3 months and eventually called police to take me to ER. Became psychotic. Was admitted to ward at a local Hospital and treated for one month as inpatient. Had ECT. Recovered from event November 25, 2021.
I was completely paralized 9 days after vaccination.  About five days later I was fighting for my life with my heart going down to 36% efficiency for three days requiring intubation.  Extensive rehab followed and I was released April 1010
After leaving pharmacy, patient had dizziness, severe dehydration, diarrhea, had to visit ER 3 times over the course of 2 weeks, patient also had heart palpitations
Psoriasis flare-up; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Psoriasis flare-up) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Plaque psoriasis.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced PSORIASIS (Psoriasis flare-up). At the time of the report, PSORIASIS (Psoriasis flare-up) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   On an unknown date, the patient experienced plaque psoriasis flare up. Moderna vaccine was also considered suspect.  It was unknown if patient was enrolled in a COVID-19 vaccine trial. On unknown date, patient received COVID-19 Vaccine manufactured by Moderna.  No treatment medication was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
administered with a probable minimally under 0.25ml booster dose; They already called the manufacturer of the syringe and they were told that they more or less are able to draw 0.24ml when they use it.; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (administered with a probable minimally under 0.25ml booster dose) and SYRINGE ISSUE (They already called the manufacturer of the syringe and they were told that they more or less are able to draw 0.24ml when they use it.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .24 ml. On an unknown date, the patient experienced UNDERDOSE (administered with a probable minimally under 0.25ml booster dose) and SYRINGE ISSUE (They already called the manufacturer of the syringe and they were told that they more or less are able to draw 0.24ml when they use it.). At the time of the report, UNDERDOSE (administered with a probable minimally under 0.25ml booster dose) and SYRINGE ISSUE (They already called the manufacturer of the syringe and they were told that they more or less are able to draw 0.24ml when they use it.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant Products were reported. No Treatment information was reported.
Chills; Fever; Body pain; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 35-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Ew0164) via an unspecified route of administration in the right arm on 17Apr2021 at 17:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks of COVID-19 vaccine. The patient did not received any other medications in two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8733) via an unspecified route of administration in the right arm on 29Mar2021 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 03:00, the patient experienced chills, fever, body pain and fatigue. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the adverse events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, body pain and fatigue were not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
About 3 hour after vaccine, mom noted infant in car seat wakened with choking sound. P/U baby and infant eyes superiorly deviated and drooling with color change red/white (mottled) Lasted about 10-15 min. Infant went to sleep immediately after. Taken to ER. w/u negative; Normal 1 day after
Lips were blue; Shaking uncontrolably; Sweating; Skin was pale; Cold; Weak; Felt like she was dying; Puked; Backache; Injection site was red; Injection site was swollen; Headache; A spontaneous report was received from a female consumer who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the events, shaking uncontrollably, sweating, cold, puked, lips were blue, skin was pale, weak, backache, headache, felt like she was dying, injection site was red, and injection site was swollen.   The patient's medical history was not provided. No relevant concomitant medications were reported.   On 14 Jan 2021 at 2 pm, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: 012L20A) intramuscularly for prophylaxis of COVID-19 infection.   On 14 Jan 2021, at 11 pm, when the patient stood up, immediately she was shaking uncontrollably, started to sweat, felt cold, weak, pale and felt like she was dying. She puked and her lips turned blue. The patient was unsure if her neck injury was contributing to her headache and backache or if it was caused by the vaccine. An ambulance was called and they stayed with the patient but opted to not take her to the hospital. No treatment information was provided.   On 17 Jan 2021, the patient reported that she was recuperating but her injection site was still red and swollen.   Action taken with the second dose of mRNA-1273 in response to the event was not reported.   The outcome for the events, shaking uncontrollably, sweating, cold, puked, lips were blue, skin was pale, weak, backache, headache, and felt like she was dying, was considered resolving. The outcome for the events,  injection site was red and injection site was swollen, was considered not resolved.; Reporter's Comments: This case concerns a female patient, who experienced a non-serious unexpected event of cyanosis, tremor, hyperhidrosis, pallor, feeling cold, asthenia, malaise, and back pain, and non-serious expected events of injection site erythema, injection site swelling, headache, and vomiting. The events of cyanosis, tremor, hyperhidrosis, pallor, feeling cold, asthenia, malaise, and vomiting occurred 9 hrs. after first dose of mRNA-1273, lot # 012L20A. The event of injection site erythema, injection site swelling, and headache occurred on an unspecified date after first dose of mRNA-1273, lot # 012L20A. Treatment details was not provided. Based on the current available information and temporal association between the use of the product and onset of the events a causal relationship cannot be excluded.
Side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Side effects) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Side effects). At the time of the report, VACCINATION COMPLICATION (Side effects) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported  No treatment information was provided.
Dandruff; Psoriasis on face; This spontaneous case was reported by a consumer and describes the occurrence of DANDRUFF (Dandruff) and PSORIASIS (Psoriasis on face) in an elderly male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis (Moderate to severe chronic).   On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced DANDRUFF (Dandruff) and PSORIASIS (Psoriasis on face). At the time of the report, DANDRUFF (Dandruff) and PSORIASIS (Psoriasis on face) had not resolved.      No concomitant product use was reported.  Moderna covid-19 vaccine MPID was reported. Humira (Adalimumab solution for injection) was single dose pen.  No treatment information was provided.  The reporter's causality for the events of dandruff and psoriasis on face with Adalimumab solution for injection was no reasonable possibility.
Narrative:  COVID infection following COVID vaccine series 03/27, Pfizer, dose #1 04/16, Pfizer, dose #2 12/28 COVID swab, result: detected 12/20 pt cc: cough, diarrhea, exposure: unknown 1/08 pt admit Medicine cc: covid, worsening CP and SOB dx: LOS: 2 1/8 CTA PE impression: 1. No evidence for pulmonary embolus. Some individuals as detailed. 2. Multifocal areas of small peripheral predominant mixed solid and groundglass consolidation most in keeping with reported COVID 19. There is diffuse but overall mild involvement at this time. Can consider 3 month follow-up to confirm resolution given the nodular appearance in some areas. 3. Mediastinal adenopathy likely reactive. Prominent number of borderline axillary lymph nodes also favoring reactive. 1/8 abdomen u/s: Significant stool burden. Nonobstructive bowel gas pattern. No pneumoperitoneum. Excreted contrast in bilateral renal collecting systems and bladder. 1/08 1/08 PROCALCITONIN: <0.05 01/08 BNP:10.3 01/09 FIBRINOGEN:627 01/09 DDIMER: 0.6 01/09 ESR:76 1/10 FIBRINOGEN:454 1/10 DDIMBER: ESR: 60
Wife reports her husband developed an infection like 19 days after receiving the vaccine; high white blood count; Fevers; This spontaneous case was reported by a consumer and describes the occurrence of INFECTION (Wife reports her husband developed an infection like 19 days after receiving the vaccine), WHITE BLOOD CELL COUNT INCREASED (high white blood count) and PYREXIA (Fevers) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Quadriplegic infantile cerebral palsy (for 8 years).    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Mar-2021, the patient experienced INFECTION (Wife reports her husband developed an infection like 19 days after receiving the vaccine), WHITE BLOOD CELL COUNT INCREASED (high white blood count) and PYREXIA (Fevers). At the time of the report, INFECTION (Wife reports her husband developed an infection like 19 days after receiving the vaccine), WHITE BLOOD CELL COUNT INCREASED (high white blood count) and PYREXIA (Fevers) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Mar-2021, White blood cell count: High.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The 2nd dose is scheduled to take place tomorrow.She reports that he was on antibiotics his doctor prescribed for him after he got out of the hospital for a month back om the 23JAN2021; and his wife reports that when his first dose was administered to him from the vaccine; that was the last day that he took the antibiotics. He was on antibiotics at the home. She said that he hasn't been on any antibiotics since 01MAR2021.
cold chills severe aches    ibephroen made worse took gaberpentin with low dose loserazpham tylenol tissure swelling no appitite wanted sleep no bowel movements
I started having CCU - Cold Contact Urticaria on 4/26 or at least thats when I was exposed to cold and noticed hives; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the arm left on 13Apr2021 at 00:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient's medical history was reported as none. Concomitant medication included liprosine (MANUFACTURER UNKNOWN). The patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm left on 23Mar2021 at 00:00 (at the age of 62-years-old) for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Apr2021 at 00:00, the patient experienced CCU - Cold Contact Urticaria on 4/26 or at least that's when he was exposed to cold and noticed hives. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether the patient had received any treatment for the event. The clinical outcome of the event urticaria was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
This report was received from the investigator on 07 June 2010. A 26 year-old male subject with no significant medical history received the following vaccines on 07 January 2010: ACAM2000 (lot number not reported); and anthrax vaccine (other manufacturer and lot number not reported). Eleven days after vaccination, the subject was diagnosed with an acute myocardial infarction. On Day 11 (18 January 2010), the subject had a Troponin I of 0.45 (abnormal) and an abnormal electrocardiogram. The outcome was not reported. Additional information will be requested from the investigator. Note: There is no reported causality assessment as this is a safety surveillance (data mining, non-interventional) study. List of documents held by sender: None.
Pain, redness, swelling at injection site began 4-11-07. Pain with arm movement, pain in left axilla area. Patient states injection site felt like a bee sting.
With 2 hours of taking the nasal swine flu vaccine, patient's upper body (torso, arms, neck, face) broke out in red rash/hot to touch/lasted an hour - took BENADRYL pill (rash considered a severe reaction on vaccine health info) VIS form.
pt seen in ER for laceration of rt hand on 20APR95; recv Td & sutures; returned to surgical clinic 1MAY95 c/o fever, swelling/pain in arm-cont to have problems;
Moderna 8/10/21, 9/16/21. Positive on 7/13/22
Developed COVD toes one week after vaccine. Started on 4th toe on L foot and at time of reporting is now on dorsal aspects of 2nd, 3rd, and 4th toes of L foot. Toes are red and swollen, without heat, and with blisters ranging from 3mm to 8mm in size. Blisters come and go and appear in different places on dorsal and lateral aspects of toes. Issue has worsened over past 3 weeks. Have attempted to soak toes in epsom salts, puncture and drain blisters with sterile lancet, applied betadyne, and covered with bandaids. Any of these measures provides temporary relief for 2-8 hours.
Beginning a few hours after the vaccine the day of  the vaccine and into the next AM, I had diarrhea. 30 hours after receiving the vaccine, I woke up at 3 AM with itching all over my body. I had hives on both eyes. I called my Dr., who scheduled me to come in for an office visit. She examined me and recommended that I proceeded to the ER for further monitoring. There they examined me and prescribed Benadryl for 5 days and  Zantac for its antihistamine properties, as well as prescribing an EpiPen. It turned out that Zantac has been removed from the market, so I have just taken Benadryl.
Numbness in hands, mouth, and head. Palpitations. Coughing. Couldn't open mouth. Tightness of chest and throat.-- around 10:00 am   2 benadryl 25 mg tabs, epipen in right thigh. was transferred to hospital at 10:30 am
Employee received .2 cc of Pfizer instead of .3 cc which was inadvertently administrated by vaccine nurse.    NO ADVERSE REACTION, just reporting medication error.   Our Vaccine Task Force, after speaking with CDC and DOH, decided to offer the employee an additional COVID-19 vaccine dose.  Thanks.
Pt recvd vax & w/in 24 hrs of vax pts arm became severely swollen upwards from the elbow; it was noted that it was erythematous & hot to touch; also exp myalgias & t100;
PT presents with HA, fever and bodyaches x last night reports receiving JJ vaccine 1000 yesterday. denies taking medication. denies known sick contacts.
awful rash was reported as worsened/bumps under her stomach and under her breasts; she started to feel a little itchy; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 80-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09May2023 as dose 5 (booster), single (Lot number: GJ3268) at the age of 80 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: BNT162b2 (First dose: 24Aug2020, Lot: unknown, She reads from vaccine card:  and BT16267-Biontech, Expiration: unknown), administration date: 24Aug2020, when the patient was 77-year-old, for covid-19 immunisation, reaction(s): "terrible headache", "severe diarrhea"; BNT162b2 (Second dose: 15Sep2020, Lot: unknown, she reads and BNT16267-Biontech, Expiration: unknown), administration date: 15Sep2020, when the patient was 77-year-old, for covid-19 immunisation; BNT162b2 (Third dose: 02Sep2021 , Lot: FC3184, Expiration: Oct2021), administration date: 02Sep2021, when the patient was 78-year-old, for covid-19 immunisation; BNT162b2 (Fourth Dose: 17Feb2022, Lot: FJ6369 or FJ6364, thinks its a 4, Expiration: May2022), administration date: 17Feb2022, when the patient was 79-year-old, for covid-19 immunisation, reaction(s): "valve replacement of her heart aortic dissection", "valve replacement of her heart aortic dissection", "stent was also placed during this serious operation on her heart". The following information was reported: RASH (non-serious) with onset 10May2023, outcome "not recovered", described as "awful rash was reported as worsened/bumps under her stomach and under her breasts"; PRURITUS (non-serious) with onset 10May2023, outcome "not recovered", described as "she started to feel a little itchy". Therapeutic measures were taken as a result of rash, pruritus.  Additional information: She wanted to report an adverse reaction to the 5th dose of the covid vaccine, bivalent. The injection was in upper left arm because she was a high-risk person. The nurse gave the covid vaccine, not the doctor. Rash: Next day after the 5th vaccine she started to feel a little itchy, and it was progressing since and sees bumps under her stomach and under her breasts. As a treatment, taking Benadryl and used topical Benadryl lotion. No Investigations, no other Products. She was also a participant in a trial of developing the Pfizer Covid vaccine.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300190194 Same reporter/patient, same drug/different dose, different AEs.;